Literature DB >> 35106277

Use of Opioids and Outcomes of Pneumonia: Results From the US Nationwide Inpatient Sample.

Yeongjun James Park1,2,3,4,5,6,7,8, Chia-Hung Yo2, Wan-Ting Hsu3, Eric Po-Yang Tsou4,5, Yu-Chiang Wang6, Dean-An Ling7, An-Fu Lee7, Michael A Liu8, Chien-Chang Lee7.   

Abstract

BACKGROUND: Opioids have been shown to increase risk of pneumonia among susceptible population. However, the effect of opioid abuse on the outcome of pneumonia has not been evaluated at the population level. We aimed to compare the outcomes of pneumonia among patients with opioid use disorder and patients without substance use disorder using a large population database.
METHODS: We assembled a pneumonia cohort composed of 11,186,564 adult patients from the National Inpatient Sample (NIS; 2005-2014). Patients with opioid disorder were identified using the International Classification of Diseases, 9th Revision, Clinical Modification codes. We compared health-related and economic outcomes between patients with and without opioid disorders using propensity score matching (PSM) analysis to balance baseline differences. The survival differences between two groups of patients were assessed using a Cox proportional hazard model. We further explored the possibility of effect modification by interaction analyses in different populations.
RESULTS: After PSM, patients with opioid use disorder were at increased risk of ventilator use (odds ratio [OR]: 1.22, 95% confidence interval [CI]: 1.08 to 1.38, p = 0.0014) and associated with increased length of hospital stay by 0.59 days (95% CI: 0.35 to 0.83, p < 0.001), compared with those without substance use disorder. Patients with opioid use also had higher daily (228.00 USD, 95% CI: 180.51 to 275.49, p < 0.001) and total (1,875.72 USD, 95% CI: 1,259.63 to 2,491.80, p < 0.001) medical costs. Subgroup analyses showed similar results.
CONCLUSIONS: Compared with patients without any drug dependence, patients with opioid use disorders had increased risk of complications and resource utilization. This study adds evidence for increased risk for pneumonia complications in the growing patients with opioid use disorders.
Copyright © 2021 by Taiwan Society of Emergency Medicine &amp; Ainosco Press. All Rights Reserved.

Entities:  

Keywords:  National Inpatient Sample; opioids; pneumonia

Year:  2021        PMID: 35106277      PMCID: PMC8748203          DOI: 10.6705/j.jacme.202112_11(4).0001

Source DB:  PubMed          Journal:  J Acute Med        ISSN: 2211-5587


  29 in total

1.  Opioid Analgesics and the Risk of Serious Infections Among Patients With Rheumatoid Arthritis: A Self-Controlled Case Series Study.

Authors:  Andrew D Wiese; Marie R Griffin; C Michael Stein; Edward F Mitchel; Carlos G Grijalva
Journal:  Arthritis Rheumatol       Date:  2016-02       Impact factor: 10.995

2.  Risk factors for clinically recognized opioid abuse and dependence among veterans using opioids for chronic non-cancer pain.

Authors:  Mark J Edlund; Diane Steffick; Teresa Hudson; Katherine M Harris; Mark Sullivan
Journal:  Pain       Date:  2007-04-20       Impact factor: 6.961

3.  Influence of glomerular filtration rate on the clearance of vancomycin administered by continuous infusion in burn patients.

Authors:  Eric Dailly; Ronan Le Floch; Guillaume Deslandes; Michel Pannier; Pascale Jolliet
Journal:  Int J Antimicrob Agents       Date:  2008-05-06       Impact factor: 5.283

Review 4.  [Therapeutic Drug Monitoring of antiinfectives in intensive care medicine].

Authors:  N S Nosseir; G Michels; R Pfister; R Adam; M H J Wiesen; C Müller
Journal:  Dtsch Med Wochenschr       Date:  2014-09-09       Impact factor: 0.628

5.  Incident opioid drug use and adverse respiratory outcomes among older adults with COPD.

Authors:  Nicholas T Vozoris; Xuesong Wang; Hadas D Fischer; Chaim M Bell; Denis E O'Donnell; Peter C Austin; Anne L Stephenson; Sudeep S Gill; Paula A Rochon
Journal:  Eur Respir J       Date:  2016-07-13       Impact factor: 16.671

6.  Opioid Analgesic Use and Risk for Invasive Pneumococcal Diseases: A Nested Case-Control Study.

Authors:  Andrew D Wiese; Marie R Griffin; William Schaffner; C Michael Stein; Robert A Greevy; Edward F Mitchel; Carlos G Grijalva
Journal:  Ann Intern Med       Date:  2018-02-13       Impact factor: 25.391

Review 7.  Past-year prevalence of prescription opioid misuse among those 11 to 30years of age in the United States: A systematic review and meta-analysis.

Authors:  Ashly E Jordan; Natalie A Blackburn; Don C Des Jarlais; Holly Hagan
Journal:  J Subst Abuse Treat       Date:  2017-03-12

8.  The comparative pharmacodynamics of remifentanil and its metabolite, GR90291, in a rat electroencephalographic model.

Authors:  E H Cox; M W Langemeijer; J M Gubbens-Stibbe; K T Muir; M Danhof
Journal:  Anesthesiology       Date:  1999-02       Impact factor: 7.892

9.  Offset of pharmacodynamic effects and safety of remifentanil in intensive care unit patients with various degrees of renal impairment.

Authors:  Des Breen; Alexander Wilmer; Andrew Bodenham; Vagn Bach; Jan Bonde; Paul Kessler; Sven Albrecht; Soraya Shaikh
Journal:  Crit Care       Date:  2003-11-21       Impact factor: 9.097

Review 10.  Could remifentanil reduce duration of mechanical ventilation in comparison with other opioids for mechanically ventilated patients? A systematic review and meta-analysis.

Authors:  Yibing Zhu; Yinhua Wang; Bin Du; Xiuming Xi
Journal:  Crit Care       Date:  2017-08-03       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.